Literature DB >> 12889082

Mutation analysis of the parkin gene in Russian families with autosomal recessive juvenile parkinsonism.

Sergei N Illarioshkin1, Magali Periquet, Nina Rawal, Christoph B Lücking, Tatyana B Zagorovskaya, Pyotr A Slominsky, Olga V Miloserdova, Elena D Markova, Svetlana A Limborska, Irina A Ivanova-Smolenskaya, Alexis Brice.   

Abstract

Autosomal recessive juvenile parkinsonism (AR-JP) is a form of hereditary parkinsonism characterized by variable clinical presentations and caused by mutations in a novel gene, parkin, on chromosome 6q25.2-27. Until now, no Russian cases of parkin-associated AR-JP have been reported on. We recruited 16 patients from 11 Russian families with dopa-responsive movement disorders according to the following criteria: 1) family history compatible with autosomal recessive inheritance; 2) onset of symptoms at </=30 years of age; and 3) the lack of mutations in the GTP cyclohydrolase I gene (in sporadic cases). Mutation screening of the parkin gene was carried out by a semiquantitative PCR assay and direct sequencing of the coding region. Six different parkin mutations (both deletions and point mutations) were identified in the index cases from four families, including a novel point mutation in the donor splice site (IVS1+1G-->A). The majority of our parkin-associated cases were characterized by early-onset dopa-responsive parkinsonism with benign course and slow progression (5 patients from two families have been followed for as long as 18-36 years), and 1 patient had a phenotype of dopa-responsive dystonia. This first description of Russian patients with AR-JP and molecularly proven parkin mutations confirms the widespread occurrence of this polymorphic hereditary extrapyramidal disorder. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12889082     DOI: 10.1002/mds.10467

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

1.  Early-onset Parkinson's disease caused by a novel parkin mutation in a genetic isolate from north-eastern Brazil.

Authors:  Hsin F Chien; Christan F Rohé; Maria D L Costa; Guido J Breedveld; Ben A Oostra; Egberto R Barbosa; Vincenzo Bonifati
Journal:  Neurogenetics       Date:  2005-11-22       Impact factor: 2.660

2.  Reduced expression of PARK2 in manganese-exposed smelting workers.

Authors:  Ximin Fan; Ying Luo; Qiyuan Fan; Wei Zheng
Journal:  Neurotoxicology       Date:  2017-08-18       Impact factor: 4.294

3.  Effective quantitative real-time polymerase chain reaction analysis of the parkin gene (PARK2) exon 1-12 dosage.

Authors:  Maria I Shadrina; Elena V Semenova; Petr A Slominsky; Gulbahar H Bagyeva; Sergei N Illarioshkin; Irina I Ivanova-Smolenskaia; Svetlana A Limborska
Journal:  BMC Med Genet       Date:  2007-02-26       Impact factor: 2.103

4.  Mutation analysis of sporadic early-onset Alzheimer's disease using the NeuroX array.

Authors:  Imelda S Barber; Anne Braae; Naomi Clement; Tulsi Patel; Tamar Guetta-Baranes; Keeley Brookes; Christopher Medway; Sally Chappell; Rita Guerreiro; Jose Bras; Dena Hernandez; Andrew Singleton; John Hardy; David M Mann; Kevin Morgan
Journal:  Neurobiol Aging       Date:  2016-09-23       Impact factor: 4.673

Review 5.  Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.

Authors:  Karen Nuytemans; Jessie Theuns; Marc Cruts; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2010-07       Impact factor: 4.878

Review 6.  Splicing: is there an alternative contribution to Parkinson's disease?

Authors:  Valentina La Cognata; Velia D'Agata; Francesca Cavalcanti; Sebastiano Cavallaro
Journal:  Neurogenetics       Date:  2015-05-16       Impact factor: 2.660

7.  Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene.

Authors:  Valentina La Cognata; Rosario Iemmolo; Velia D'Agata; Soraya Scuderi; Filippo Drago; Mario Zappia; Sebastiano Cavallaro
Journal:  Curr Genomics       Date:  2014-06       Impact factor: 2.236

Review 8.  microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.

Authors:  Loredana Leggio; Silvia Vivarelli; Francesca L'Episcopo; Cataldo Tirolo; Salvo Caniglia; Nunzio Testa; Bianca Marchetti; Nunzio Iraci
Journal:  Int J Mol Sci       Date:  2017-12-13       Impact factor: 5.923

Review 9.  Advances with microRNAs in Parkinson's disease research.

Authors:  Liuqing Ma; Liangming Wei; Fei Wu; Zhenhua Hu; Zhenguo Liu; Weien Yuan
Journal:  Drug Des Devel Ther       Date:  2013-10-01       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.